Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Ítems similars

• Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
  per: Ohe, Yuichiro, et al.
  Publicat: (2018)
• Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
  per: La Monica, Silvia, et al.
  Publicat: (2017)
• Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
  per: Gray, Jhanelle E., et al.
  Publicat: (2019)
• Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
  per: Imamura, Fumio, et al.
  Publicat: (2020)
• First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
  per: Ricciuti, Biagio, et al.
  Publicat: (2018)